The effects of verapamil on junctional and sinoatrial activity were studied in eight patients with third-degree atrioventricular block and stable junctional rhythms. After intravenous infusion of verapamil three steady-state levels were reached as follows: 34 +-16 (SS,), 68 + 30 (SS2), and 129 ± 54 (SS3) ng/ml. At each steady-state level, spontaneous sinus and junctional cycle lengths, QT intervals, junctional recovery times after ventricular pacing, blood pressure, and circulating catecholamine concentrations were measured. These measurements were compared with observations made during an identical protocol (except for the exclusion of verapamil infusions) on a control day. No significant changes were detected in the spontaneous sinus or junctional cycle length, junctional recovery times at a fixed pacing cycle length, blood pressure, or circulating catecholamine concentrations during the control day. In response to verapamil, the mean junctional cycle length decreased from abaseline value of 1320 +
SS1, SS2, and SS3 (p < .01). Sinus cycle length (msec) was unaffected or slightly lengthened from 749 + 165 at baseline to 821 ± 222 at SS,, 831 ± 222 at SS2, and 817 + 175 at SS3 (NS). Mean blood pressure, circulating catecholamine concentrations, and corrected QT intervals were also unchanged by verapamil. Verapamil enhanced junctional pacemaker activity in patients with third-degree atrioventricular block, suggesting that (1) these rhythms originate in cells that are not suppressed by the slowchannel antagonism of verapamil and (2) the acceleration of junctional activity seen in response to verapamil reflects a verapamil effect rather than toxicity. Circulation 71, No. 3, 450-457, 1985. THE MAJOR electrophysiologic action of verapamil is to depress the slow response of pacemaker cells in the sinus node and in specialized conduction cells of the atrioventricular node, which results in slowing of the sinus node discharge rate and conduction through the atrioventricular node in conscious man. Several recent observations in man, however, suggest that by increasing atrioventricular block, verapamil also promotes the emergence of nodal pacemaker activity. During the clinical use of verapamil to slow the ventricular response rate in atrial fibrillation, a regulariza- Dr. Nielsen was supported by the Albert Hyman Fellowship of The North American Society for Electrophysiology and Pacing. tion (less than 15% variation in the RR interval of the ventricular response rate) has been noted'`6 and hypothesized to be the result of complete atrioventricular block and junctional rhythm.3 Also, an increased frequency of junctional rhythms has been observed in patients receiving verapamil for the prophylactic management of paroxysmal supraventricular tachycardia.' 8 The current study was designed to investigate the differential effects of varying concentrations of verapamil on sinoatrial vs junctional automaticity in man and to correlate these effects with blood pressure and circulating catecholamine responses.
Method
Patients (table 1) . Eight patients (five men and three women) ranging in age from 29 to 92 years (mean + SD, 61 + 21) with third-degree atrioventricular block and stable junctional rhythms were studied. Junctional rhythms were defined by a narrow QRS complex (' 100 msec and axis -15--+ 65 degree), a regular rate, and atrioventricular dissociation resulting from third-degree atrioventricular block. The cause of complete atrioventricular block was idiopathic in four (one of the four had also received a diagnosis of sick sinus syndrome) and His bundle disease in one, and appeared after mitral valve replacement in one, after accessory pathway ablative surgery in one, and CIRCULATION after transvenous catheter ablation of the atrioventricular conduction system in one. The site of atrioventricular block was identified at electrophysiologic study in six patients (Nos. 1, 2, 3, 4, 5, and 7). In four, His bundle depolarizations preceded the QRS complex (Nos. 2, 3, 5, and 7). The pacemaker in these patients was either within the lower regions of the atrioventricular node or within the His bundle. Two patients had block below the His: in patient 1, no His bundle depolarization could be demonstrated after transvenous catheter ablation of the atrioventricular conduction system in the area of previous recording of the maximal His potential and in patient 4 block occurred spontaneously within the His bundle. No systematic evaluation of sinus node function was performed.
Seven of the eight patients had permanently implanted programmable pacemakers (four were dual-chamber and three were single-chamber devices) and one patient had a temporary transvenous lead. The duration of third-degree atrioventricular block before the study was 2 months to 7 years in the patients with permanent devices. The pacemakers had been implanted 2 to 10 months before this study in six of the seven patients and 4 days before study in one. The patient with a temporary pacemaker was studied 2 days after transvenous catheter ablation of the atrioventricular conduction system. Cardiac medications included furosemide in two patients and hydrochlorothiazide in one, clonidine in one, and digoxin in one patient. Other 7) or to the coronary care unit (n = 1) at least 1 day before the study. Patients were studied during the same hours on 2 consecutive days: a control and a verapamil infusion day. The protocol on the 2 days was identical except that verapamil was infused on only 1 day (day 2). Before the study began, two venous catheters were placed in the forearm of each patient and electrocardiographic monitoring was begun. After 30 min supine bed rest, Vol. 71, No. 3, March 1985 = chronic obstructive pulmonary pacemakers were programmed down in a stepwise fashion to the lower rate limit (30 beats/min in most cases) and baseline measurements were obtained after 30 min of spontaneous junctional rhythm. These measurements included those of spontaneous sinus and junctional cycle length, QT interval during junctional rhythm9 and at a constant pacing rate,'0 junctional recovery times after 60 sec of ventricular pacing at 95% to 50% of the spontaneous junctional cycle length, ventricular pacing threshold (and atrial threshold for dual-chamber devices), and blood pressure (by cuff sphygmomanometer). Venous blood was drawn for determination of norepinephrine, epinephrine, and verapamil concentrations. Verapamil was administered intravenously by a serial rapid (½/2 hr) then a slower (1 hr) six-stage infusion protocol; drug infusion rates were calculated so that approximate steady-state verapamil concentrations of 30, 60, and 120 ng/ml would be reached after infusions of 1.5, 3, and 4.5 hr. At the end of each rapid infusion, blood pressure and spontaneous cycle lengths were measured. During the last 10 min of each slower or steady-state infusion, these measurements plus junctional recovery times after ventricular pacing, pacing thresholds, QT intervals (during junctional rhythm and at a fixed ventricular pacing rate), serum catecholamine levels, and verapamil concentrations were measured. On the control day, all measurements were made at the same time points. Patients remained at bed rest throughout the studies.
Plasma drug levels. Five milliliters of heparinized blood was drawn at baseline and twice (15 min apart) during the later phases of each steady-state infusion to assess the stability of plasma concentrations. Verapamil concentrations were determined by gas-liquid chromatography." Plasma catecholamines. At baseline and immediately before the determination ofjunctional recovery times at the end of each steady-state infusion, 8 ml of blood was drawn into chilled test tubes, with EGTA and glutathione as preservatives, and immediately placed on ice and transferred to a refrigerated centrifuge. After separation samples were stored at -40°C until assay by high-pressure liquid chromatography with electrochemical detection'2 (n = 7) or radioimmunoassay (n = 1).13
Electrophysiologic measurements. The surface electrocardiographic lead demonstrating the largest P wave was moni-tored during the studies and recordings were made with an Electronics for Medicine VR6 recorder with paper speeds of 100 mm/sec. At the end of each infusion, spontaneous junctional and sinus cycle lengths were recorded, and then ventricular pacing for determination of junctional recovery times was performed. Ventricular pacing was performed at the permanently programmed ventricular output in the seven patients with implanted pacemakers and at twice diastolic threshold in the one patient with a temporary lead. The junctional recovery time was measured from the last paced QRS to the onset of the first escape QRS complex of the same morphology as that of the control beats. Because of the lower rate limit of 30 beats/min in the permanently implanted pacemakers, measurements of recovery times greater than 2000 msec could not be made. Pacing threshold was determined by gradually increasing either pulse amplitude (three patients) or pulse duration (five patients) until 1:1 capture was achieved.
Statistical analysis. Changes in measurements over time were analyzed by either parametric analysis of variance for repeated measures and Dunnett's test to detect for individual differences when data were normally distributed or Friedman's nonparametric analysis of variance with multiple comparisons and one-tailed probability for those data not distributed normally. Student's paired t test with two-tailed probability was used to test for differences between verapamil concentrations in samples obtained during the same steady-state period. Values are given as mean + SD.
Results
Verapamil concentrations. During the first presumed steady-state period (SS), verapamil concentrations were 34 16 ng/ml at the time of the first sampling and 33 + 16 ng/ml at the end of the infusion. During the second steady-state infusion (SS2) concentrations were 68 ± 28 and 68 ± 32 ng/ml, and during the third period (SS3) levels were 132 57 and 126 + 50 ng/ml. No significant differences were detected between the concentrations within each presumed steady-state infusion period, documenting that stable steady-state plasma verapamil concentrations were reached.
Electrophysiologic measurements
Sinus cycle length ( figure 1, table 1 ). The mean sinus cycle length for the group on the control day was 765 ± 204 msec after 30 min of spontaneous junctional rhythm and was 754 205 msec at the time of SS , 755 ± 213 msec at SS2, and 757 ± 242 msec at SS,. No significant differences in sinus cycle length were found during the period of monitoring on the control day.
During verapamil infusions, the mean sinus cycle length increased from a baseline value of 749 + 165 msec to 821 222 msec at SS, 831 ± 222 msec at SS2, and 817 175 msec at SS3. This lengthening of the sinus cycle did not amount to a statistically significant trend when values were analyzed for the entire group. However, in some individuals the sinus cycle length was prolonged by increasing concentrations of In contrast, in all patients the junctional cycle length decreased (p < .01) with increasing plasma concentrations of verapamil ( figure 3 ). At baseline, the mean junctional cycle length was 1320 239 msec and was not significantly different from the value on the control day. At SS, (or 33 ng/ml verapamil) the junctional cycle length was 1254 210 msec. At SS2 (68 ng/ml verapamil) the junctional cycle length was 1 199 214 msec and was decreased further to 1069 + 151 msec at SS3 with a plasma verapamil concentration of approximately 128 ng/ml. Comparisons between the baseline and steady-state values showed the decreases in junctional cycle lengths to be statistically significant (p < .01) for the SS, and SS3 verapamil concentrations.
Concentrations of 30 ng/ml verapamil did not significantly shorten the junctional cycle length. QT 1000  980  2  880  900  810  840  880  860  870  1450  1500  1490  1490  1520  1540  1540  3  1000  1000  1010  960  1000  760  1120  1190  1200  1200  1150  1130  1180  1200  4  670  670  620  570  610  570  590  1240  1220   -1270  5  930  910  960  940  1020  960  980  1680  1760  1620  1620  1900  1700  1680  6  860  865  840  805  700  750  720  1400  1395  1440  1440  1400  1420  1400  7  560  560  580  600  600  580  560  1140  1160  1160  1200  1100  1140 Junctional recovery times. Junctional recovery times after ventricular pacing were measured at the same pacing cycle lengths on both study days at baseline and at each steady-state verapamil level. As has been described by others,14, junctional recovery times were CIRCULATION 454 j the control day in six of the seven patients for whom complete data were obtained (the junctional recovery times on the verapamil day fell within the 95% confidence limits of those obtained on the control day in patient 2). Control day data were incomplete for patient 5. Pacing thresholds. No significant change in ventricular pacing thresholds was seen during administration of verapamil. The mean ventricular threshold was 2.7 + 1.3 ,uJ at baseline and 2.8 ± 1.7, 2.8 + 1.4, and 2.6 ± 1.4 gJ at SS1, SS2, and SS3. Atrial thresholds were similarly unaffected by verapamil (range of mean values 4.0 to 4.3 ,uJ).
Blood pressure. On the control day, mean arterial pressures ranged from 86 ± 12 mm Hg at baseline to 80 ± 8 mm Hg. Baseline values were slightly lower on the day of infusion of verapamil, with a mean of 79 + 8 mm Hg. This may have reflected the effects of an additional day of bed rest or a familiarity with the testing procedures. No significant change in blood pressure was noted during administration of verapamil ( figure 5 ).
Circulating catecholamines
Norepinephrine. During the control study, circulating levels of norepinephrine ranged from 246 + 123 to 268 + 96 pg/ml. No significant change was observed during the approximately 5 hr of testing. On the day of the verapamil infusion, the mean levels of norepinephrine at baseline were 252 ± 40 pg/ml, not significantly different from values on the control day. During verapamil administration, norepinephrine concentrations were 269 113 pg/ml at SS,, 263 + 98 pg/ml at SS2, and 314 ± 147 pg/ml at SS3 (figure 6). No concentration-dependent effect was detected. Epinephrine. No significant trends with respect to epinephrine levels were detected on either study day. On the control day, the mean baseline value was 32 ± 25 pg/ml; values at SS,, SS2, and SS3 were 38 + 20, 42 + 24, and 36 23 pg/ml. On the day of infusion of verapamil, the mean concentration was 48 + 14 pg/ml at baseline, and 31 39 (undetectable in one patient), 45 29, and 41 27 pg/ml at SS,, SS2, and SS3.
Discussion
Numerous investigators have shown that slow-channel activity is critical to the automaticity or spontaneous phase-four diastolic depolarization found in cells of the sinoatrial node.'6 Slow-channel blockade with verapamil or other slow channel-blocking drugs results in inhibition of the activity of these cells.'7' 1 ' Suppression of sinus nodal activity by slow-channel blockade with verapamil has been demonstrated in ani-mals19' 20 and man. 2' In contrast, during verapamil administration to patients with supraventricular arrhythmias, we observed (1) concentration-dependent regularization of the ventricular response during atrial fibrillation and (2) an increased incidence of accelerated junctional rhythms. These observations led to the hypothesis that verapamil or slow-channel blockade exerts a differing influence on the automaticity of various cardiac pacemaker tissues. Specifically, they indicate that enhancement rather than depression ofjunctional pacemaker activity occurs in response to administration of verapamil in man. The purpose of this study was to determine the effects of increasing concentrations of verapamil on sinoatrial nodal automaticity vs junctional automaticity in conscious man under experimental conditions designed to minimize hypotensive or reflex responses to verapamil.
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We studied patients with third-degree atrioventricular block and stable narrow QRS junctional rhythms. Despite the differing causes and sites of atrioventricular block, the qualitative response to verapamil was the same. In all patients, spontaneous junctional cycle lengths and junctional recovery times after ventricular pacing decreased with increasing verapamil concentrations of 60 to 200 ng/ml. In contrast, no change or depression of sinus pacemaker activity was seen. No significant change in blood pressure was seen during the study and there was no significant rise in circulating norepinephrine or epinephrine levels. These findings suggest that circulating catecholamine stimulation was not a major contributing factor to the observed changes in junctional activity. The lack of change in the corrected QT interval during junctional rhythm9 or in the QT during ventricular pacing10 further argues against catecholamine22 or prolonged sympathetic nerve23 stimulation.
It is more difficult to eliminate the possibility of alterations in localized adrenergic sympathetic tone since we were unable to serially measure cardiac or atrioventricular nodal cell catecholamine tumover rates or /3-receptor numbers or affinity. It is likely in fact that intact autonomics and/or local catecholamines played some role in our results. Urthaler and James24 have shown that atrioventricular junctional escape rhythms in dogs are not arrested by infusion of verapamil or propranolol into an atrioventricular nodal artery but are almost completely suppressed by the combination of verapamil and adrenergic deprivation. Their data concur with our findings that verapamil does not suppress escape atrioventricular junctional pacemakers in man. Further extrapolation of their hypotheses to man have been supported by reports of asystole after the combination of verapamil and /3-blockade25 despite the maintenance of junctional rhythms during third-degree atrioventricular block after massive doses of verapamil alone.26 It is therefore likely that intact autonomics and/or local catecholamines also played a role in our results; nonetheless, a direct relationship to the plasma concentration of verapamil was documented.
A change in parasympathetic activity is unlikely to be a major influence since it has previously been shown that parasympathetic blockade with atropine has no effect on cycle lengths of junctional rhythms in patients with intra-Hisian block and variable effects on junctional rhythms in patients with supra-Hisian block. '5 Two of our patients had block at or below the His bundle and thus one can presume no significant parasympathetic influences in these patients. The fact 456 that responses in these patients were the same as those in the patients with supra-Hisian block makes parasympathetic factors unlikely to have been of significant influence.
Enhanced impulse formation in the atrioventricular nodal or junctional tissues is usually observed in man when there is some delay in atrioventricular conduction. Previously this has been seen most commonly in the presence of digitalis therapy, rheumatic fever, acute myocardial infarction, or after cardiac surgery. 27 The precise origin of these junctional rhythms has been presumed to be from either the lower atrioventricular node28 or the His bundle.29 30 Our results suggest that whatever the origin of the junctional rhythms occurring in association with complete atrioventricular block in man, the activity of the cells responsible for these rhythms is neither slow-channel dependent nor suppressed by slow-channel antagonism with verapamil. Furthermore, the acceleration of junctional activity in response to verapamil suggests that junctional rhythms during verapamil therapy should not be considered a toxic response but simply a reflection of the pharmacologic effect of verapamil.
